Late-stage cancers often recur more aggressively after treatment. This research identifies the specific dendritic cell types found inside tumors, distinguishing “good” anti-cancer cells from “bad” tumor-promoting ones. Using this knowledge, a tailored dendritic-cell vaccine is being developed and tested in an ovarian-cancer-like mouse model to prevent relapse.

This research investigates a novel two-drug therapy for ovarian cancer that kills cancer cells without harming healthy tissues and partially reactivates the suppressed immune system. The PhD work explores how this immune “reawakening” occurs, aiming to identify new strategies to enhance it and create more effective, resistance-proof treatments.